Advertisement

Prodrugs pp 1173-1183 | Cite as

Case Study: Capecitabine: A Prodrug of 5-Fluorouracil

  • Nobuo Shimma
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

Capecitabine (2), is an off-white crystalline solid with and aqueous solubility of 26 mg/mL. It is sold as Xeloda® and is a prodrug said to achieve selective delivery of 5-fluorouracil (5-FU, 1) to tumors by sequential activation of the prodrug with endogenous enzymes preferentially located in the human liver and tumor tissues see Fig. 1). Capecitabine was first approved in the US in 1998 for the treatment of metastatic breast cancer that is refractory to standard chemotherapy with paclitaxel and anthracycline-containing regimen; it has now been used for the treatment of metastatic breast and colorectal cancers in more than 70 countries. It was designed to achieve greater selectivity than its active form, 5-FU (1)

Keywords

Thymidine Phosphorylase Cytidine Deaminase Dihydropyrimidine Dehydrogenase Bone Marrow Toxicity Pyrimidine Nucleoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chabner BA and Longo DL. In Cancer Chemotherapy and Biology: Principles and Practice 2nd Ed. Lippincott-Raven Ed., Philadelphia, New York, 1996:149–211 and 213–233Google Scholar
  2. Cook AF, Holman MJ, Kramer MJ, and Trown PW. Fluorinated Pyrimidine Nucleosides. 3. Synthesis And Antitumor Acitivity of a Series of 5′-Deoxy-5-fluoropyrimidine Nucleosides. J Med Chem 1979; 22:1330–1335PubMedCrossRefGoogle Scholar
  3. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, and Ishitsuka H. Cytokines Induce Thymidine Phosphorylase Expression in Tumor Cells and Make Them More Susceptible To 5′-Deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32:333–338PubMedCrossRefGoogle Scholar
  4. Hattori K, Kohchi Y, Oikawa N, Suda H, Ura M, Ishikawa T, Miwa M, Endoh M, Eda H, Tanimura H, Kawashima A, Horii I, Ishitsuka H, and Shimma N. Design and Synthesis of the Tumor-activated Prodrug of Dihydropyrimidine Dehydrogenase (DPD) Inhibitor RO0094889 for Combination Therapy with Capecitabine. Bioorg Med Chem Lett 2003; 13:867–872PubMedCrossRefGoogle Scholar
  5. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, and Ishitsuka, H. Tumor Selective Delivery of 5-Fluorouracil by Capecitabine, a New Oral Fluoropyrimidine Carbamate, in Human Cancer Xenografts Biochem Pharmacol 1998a; 55:1091–1097PubMedCrossRefGoogle Scholar
  6. Ishikawa T, Fukase Y, Yamamoto T, Sekiguchi F, and Ishitsuka H. Antitumor Activities of a Novel Fluoropyrimidine, N 4-Pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (Capecitabine) Biol Pharm Bull 1998b; 21:713–717PubMedGoogle Scholar
  7. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, and Ishitsuka H. Positive Correlation between the Efficacy of Capecitabine and Doxifluridine and the Ratio of Thymidine Phosphorylase to Dihydropyrimidine Dehydrogenase Activities in Tumors in Human Cancer Xenografts Cancer Res 1998c; 58:685–690PubMedGoogle Scholar
  8. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, and Maruyama HB. Role of Uridine Phosphorylase for Antitumor Activity Of 5′-Deoxy-5-fluorouridine. Gann (Jpn J Cancer Res) 1980; 71:112–123Google Scholar
  9. Kawashima A, and Horii I. In Proceedings of the 53 rd Annual Meeting of the Japanese Cancer Association (October, 1994, Nagoya). Abstract No. 2411, pp.658Google Scholar
  10. Kono A, Hara Y, Sugata, S, Karube Y, Matsushima Y, and Ishitsuka H. Activation of 5′-Deoxy-5-fluorouridine by Thymidine Phosphorylase in Human Tumors. Chem Pharm Bull 1983; 31:175–178PubMedGoogle Scholar
  11. Kreis W, Watanabe KA, and Fox JJ. Structural Requirements for the Enzymic Deamination of Cytosine Nucleosides Helv Chim Acta 1978;61:1011–1016CrossRefGoogle Scholar
  12. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T Mori K, Shimma N, Umeda I, and Ishitsuka, H. Design of a Novel Oral Fluoropyrimidine Carbamate, Capecitabine, which Generates 5-Fluorouracil Selectively in Tumours by Enzymes Concentrated in Human Liver and Cancer Tissue Eur J Cancer 1998; 34:1274–1281PubMedCrossRefGoogle Scholar
  13. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G., Fumoleau P, Jones S, Lui W-Y, Mauriac L, Twelves C, Van Hazel G., Verma S, and Leonard R. Superior Survival with Docetaxel/capecitabine Combination Therapy in Anthracycline-Pretreated Patients: Phase III Trial Results. J Clin Oncol 2002; 12:2812–2823CrossRefGoogle Scholar
  14. Reigner B, Blesch K, and Weidekamm E. Clinical Pharmacokinetics of Xeloda. Clin. Pharmacokinet 2001; 40:85–104PubMedCrossRefGoogle Scholar
  15. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, and Ishitsuka H. Induction of Thymidine Phosphorylase Activity and Enhancement of Capecitabine Efficacy by Taxol/Taxotere in Human Cancer Xenografts Clin Cancer Res 1998; 4:1013–1019PubMedGoogle Scholar
  16. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, and Ishitsuka H. X-Ray Irradiation Induces Thymidine Phosphorylase and Enhances the Efficacy of Capecitabine (Xeloda) in Human Cancer Xenografts. Clin Cancer Res 1999; 5:2948–2953PubMedGoogle Scholar
  17. Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, Miwa M, Ura M, Sawada N, Tahara H, Kuruma I, Horii I, and Ishitsuka H. The Design and Synthesis of a New Tumor-selective Fluoropyrimideine Carbamate, Capecitabine. Bioorganic Med. Chem. 2000; 8:1697–1706CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Nobuo Shimma
    • 1
  1. 1.Kamakura Research LaboratoriesChugai Pharmaceutical Co. Ltd.KamakuraJapan

Personalised recommendations